Drugs / IL-12 DNA
IL-12 DNA
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05781542 | Apr 2023 → Oct 2024 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00195312 | Aug 2005 → Aug 2007 | HIV infectious disease | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00111605 | ? → May 2008 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-12 DNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00195312 ↗ |
| Known as | DNA IL-12 | “PB has licensed a portfolio of issued and pending patents from Pfizer in the area of DNA vaccines, is actively developing DNA IL-12 as a product” PMID 22242162 ↗ Jan 2012 |
| Known as | IL-12 DNA adjuvant | “Injection IL-12 DNA adjuvant intramuscularly into the deltoid” NCT00111605 ↗ |
| Modality | Vaccine | “recombinant DNA vaccine” NCT05781542 ↗ |